News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Reanalysis of Urothelial Cancer Chemoimmunotherapy Trials With Differential Censoring
opmed.doximity.com
Jan 29, 2025, 07:56

Reanalysis of Urothelial Cancer Chemoimmunotherapy Trials With Differential Censoring

Laura Bukavina, Urologic Oncologist at Cleveland Clinic Urology, shared a post on X:

“When control patients drop out for better options, outcomes get skewed equals perceived inferiority bias

In Bladder Cancer trials this bias inflated PFS/OS for chemo + IO. Adjustments erased OS (nivolumab, CheckMate901) and PFS (pembrolizumab, KEYNOTE-361). RCT are not perfect.”

Reanalysis of Urothelial Cancer Chemoimmunotherapy Trials With Differential Censoring

Authors: Tomer Meirson, Jonathan Ofer,  Noa Zimhony-Nissim, Avital Bareket-Samish,  Gal Markel,  Victoria Neiman, Nathan Cherny, Daniel A. Goldstein,  Bishal Gyawali, Ian Tannock, Eli Rosenbaum.

Reanalysis of Urothelial Cancer Chemoimmunotherapy Trials With Differential Censoring

 

Avital Bareket-Samish Bishal Gyawali cancer Daniel A. Goldstein Eli Rosenbaum Gal Markel Ian Tannock Jonathan Ofer Laura Bukavina Nathan Cherny Noa Zimhony-Nissim OncoDaily Oncology Tomer Meirson Victoria Neiman
Special Coverage
Blog
Jan 29, 2025, 07:56
Reanalysis of Urothelial Cancer Chemoimmunotherapy Trials With Differential Censoring
Blog
Jan 29, 2025, 07:53
Krishan Jethwa: Prognostic significance of detectable ctDNA in the NEO-trial
Blog
Jan 29, 2025, 07:52
Kelsey Pan: Encorafenib, cetuximab and nivolumab in patients with BRAF V600E mutated mCRC
Blog
Jan 29, 2025, 07:48
How do copy no. deletions in STK11, KEAP1 and SMARCA4 impact outcomes in NSCLC?
Blog
Jan 29, 2025, 07:46
Krishan Jethwa: Highlighting comparison of OPRA vs AIO-12
Blog
Jan 29, 2025, 07:45
Eric Singhi: Reducing IRRs with IV amivantamab in EGFR+ mNSCLC post osimertinib/chemotherapy
Blog
Jan 29, 2025, 07:43
Pashtoon Kasi: Immunotherapy's Potential in Refractory Patients with Liver Metastases
Blog
Jan 29, 2025, 07:41
Cathy Eng: Role of ctDNA and the impact on decision making in stage II/III colon cancer disease
Blog
Jan 29, 2025, 07:39
Sharlene Gill: Practice-changing ALASCCA ph3 trial
Blog
Jan 29, 2025, 07:38
Mark Lewis: Learning the Power of Saying No
Blog
Jan 29, 2025, 07:37
Bishal Gyawali: Reanalysis of Urothelial Cancer Chemoimmunotherapy Trials With Differential Censoring
Blog
Jan 29, 2025, 07:35
Petros Grivas: Inspired after interacting with so awesome colleagues at AUC3